High-throughput experimentation (HTE) has revolutionized the pharmaceutical industry, most notably allowing for rapid screening of compound libraries against therapeutic targets. The past decade has also witnessed the extension of HTE principles toward the realm of small-molecule process chemistry. Today, most major pharmaceutical companies have created dedicated HTE groups within their process development teams, invested in automation technology to accelerate screening, or both. The industry's commitment to accelerating process development has led to rapid innovations in the HTE space. This review will deliver an overview of the latest best practices currently taking place within our teams in process chemistry by sharing frequently studied transformations, our perspective for the next several years in the field, and manual and automated tools to enable experimentation. A series of case studies are presented to exemplify state-of-the-art workflows developed within our laboratories.

A strategy for the installation of small alkyl fragments onto pharmaceutically relevant aliphatic structures has been established via metallaphotoredox catalysis. Herein, we report that tris(trimethylsilyl)silanol can be employed as an effective halogen abstraction reagent that, in combination with photoredox and nickel catalysis, allows a generic approach to Csp3─Csp3 cross-electrophile coupling. In this study, we demonstrate that a variety of aliphatic drug-like groups can be successfully coupled with a number of commercially available small alkyl electrophiles, including methyl tosylate and strained cyclic alkyl bromides. Moreover, the union of two secondary aliphatic carbon centers, a long-standing challenge for organic molecule construction, has been accomplished with a wide array of structural formats. Last, this technology can be selectively merged with Csp2─Csp3 aryl–alkyl couplings to build drug-like systems in a highly modular fashion.

Cluster excision of polymeric {Mo3S7Cl4}n phases with chiral phosphane (+)-1,2-bis[(2R,5R)-2,5-(dimethylphospholan-1-yl)]ethane ((R,R)-Me-BPE) or with its enantiomer ((S,S)-Me-BPE) yields the stereoselective formation of the trinuclear cluster complexes [Mo3S4{(R,R)-Me-BPE}3Cl3]+ ([(P)-1]+) and [Mo3S4{(S,S)-Me-BPE}3Cl3]+ ([(M)-1]+), respectively. These complexes possess an incomplete cuboidal structure with the metal atoms defining an equilateral triangle and one capping and three bridging sulfur atoms. The P and M symbols refer to the rotation of the chlorine atoms around the C3 axis, with the capping sulphur atom pointing towards the viewer. Incorporation of copper into these trinuclear complexes affords heterodimetallic cubane-type compounds of formula [Mo3CuS4{(R,R)-Me-BPE}3Cl4]+ ([(P)-2]+) or [Mo3CuS4{(S,S)-Me-BPE}3Cl4]+ ([(M)-2]+), respectively, for which the chirality of the trinuclear precursor is preserved in the final product. Cationic complexes [(P)-1]+, [(M)-1]+, [(P)-2]+, and [(M)-2]+ combine the chirality of the metal cluster framework with that of the optically active diphosphane ligands. The known racemic [Mo3CuS4(dmpe)3Cl4]+ cluster (dmpe = 1,2-bis(dimethylphosphanyl)ethane) as well as the new enantiomerically pure Mo3CuS4 [(P)-2]+ and [(M)-2]+ complexes are efficient catalysts for the intramolecular cyclopropanation of 1-diazo-5-hexen-2-one (3) and for the intermolecular cyclopropanation of alkenes, such as styrene and 2-phenylpropene, with ethyl diazoacetate. In all cases, the cyclopropanation products were obtained in high yields. The diastereoselectivity in the intermolecular cyclopropanation of the alkenes and the enantioselectivity in the inter- or intramolecular processes are only moderate.

Photoredox catalysis has emerged as a powerful and versatile platform for the synthesis of complex molecules. While photocatalysis is already broadly used in small-scale batch chemistry across the pharmaceutical sector, recent efforts have focused on performing these transformations in process chemistry due to the inherent challenges of batch photocatalysis on scale. However, translating optimized batch conditions to flow setups is challenging, and a general approach that is rapid, convenient, and inexpensive remains largely elusive. Herein, we report the development of a new approach that uses a microscale high-throughput experimentation (HTE) platform to identify optimal reaction conditions that can be directly translated to flow systems. A key design point is to simulate the flow-vessel pathway within a microscale reaction plate, which enables the rapid identification of optimal flow reaction conditions using only a small number of simultaneous experiments. This approach has been validated against a range of widely used photoredox reactions and, importantly, was found to translate accurately to several commercial flow reactors. We expect that the generality and operational efficiency of this new HTE approach to photocatalysis will allow rapid identification of numerous flow protocols for scale.

Chiral dirhodium(II) compounds, Rh 2 (O 2 CR) 2 (pc) 2 (pc ) ortho-metalated arylphosphine), with a head-to-tail arrangement (1-21) are used in the cyclopropanation of R-diazo ketones. The influence of catalyst ligands and substrate structure on enantioselectivity is studied. Temperature and solvent dependence assays are performed, the best ee values being obtained in refluxing pentane. Results compare favorably with those reported in the literature using Ru, Cu, and other Rh(II) catalysts.